THE COLUMN GROUP
THE COLUMN GROUP is a Pre-seed, Seed, Series A, Series B and Series C+ fund in the US and Europe writing $20M–$60M checks into Healthcare, healthcare-tech, oncology, immunology, genetic-medicines and neuroscience.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, healthcare-tech, oncology, immunology, genetic-medicines, neuroscience
- Check size
- $20M–$60M
- Invests in
- US-wide, Europe
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2007
- Assets under management
- $4.2B
- Website
- thecolumngroup.com
Thesis
The Column Group (TCG) is a San Francisco-based venture capital firm founded in 2007, specializing in early-stage drug discovery and development. With a science-driven approach, TCG aims to build fundamentally strong healthcare companies by leveraging unique scientific platforms and therapeutic potential. Their investment strategy focuses on companies with exceptional scientific foundations, prioritizing a select cohort with great ideas, world-class founders, and top-tier talent. TCG invests across pre-seed, seed, Series A, B, C, and D rounds, with a strong emphasis on Series A and B for platform biotechnology companies. While primarily focused on the United States, they also invest in companies emerging from European academic collaborations. TCG typically leads or co-leads investments, committing $20 million to $60 million in initial institutional rounds for platform biotech companies. Their sector focus includes oncology, immunology, genetic medicines, and neuroscience. The firm has significant assets under management, with reported figures around $4.2 billion across multiple private funds.
Common questions
Does THE COLUMN GROUP invest at the Pre-seed stage?
Yes. THE COLUMN GROUP lists Pre-seed, Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does THE COLUMN GROUP write?
THE COLUMN GROUP writes $20M–$60M checks.
Where does THE COLUMN GROUP invest?
THE COLUMN GROUP invests in the US and Europe.